T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2024
0mins
Should l Buy CAH?
Source: Newsfilter
T2 Biosystems Licensing Strategy: T2 Biosystems plans to license its proprietary technology for direct-from-whole-blood detection of sepsis-causing pathogens, aiming to generate non-dilutive capital and create a new royalty revenue stream while accelerating the adoption of these diagnostics in healthcare.
Competitive Advantage: The company's FDA-cleared products offer rapid detection of pathogens without the delays associated with traditional blood culture methods, positioning T2 Biosystems favorably against competitors reliant on longer turnaround times for results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 211.310
Low
209.00
Averages
225.18
High
244.00
Current: 211.310
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Expands Ac-225 Production Capacity Significantly
- Production Capacity Boost: Cardinal Health has added a high-capacity production line at its Center for Theranostics Advancement in Indianapolis, significantly increasing the supply of cGMP-compliant Ac-225 to meet the growing demand for cancer therapies.
- Clinical Trial Support: To date, Cardinal Health's Ac-225 has supported over 15 clinical trials worldwide, reflecting the company's extensive engagement in advancing targeted alpha therapies and enhancing its position in pharmaceutical innovation.
- Market Demand Response: Since announcing routine global production at scale at the end of 2024, Cardinal Health has quadrupled its weekly output, with expectations to continue increasing production capacity in 2026 to meet the rapidly growing demand for targeted alpha therapies.
- Supply Chain Assurance: According to VP Shane Thrasher, expanding Ac-225 production capacity is a critical advancement for the industry and patients, ensuring reliable access to targeted alpha therapies and preparing for larger commercial volumes in the future.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Cardinal Health to Release Q3 FY2026 Financial Results on April 30
- Earnings Release Schedule: Cardinal Health is set to release its third-quarter financial results for fiscal year 2026 on April 30, prior to the opening of trading on the New York Stock Exchange, ensuring timely access to critical information for investors.
- Webcast Discussion: The company will host a webcast discussion of the financial results starting at 8:30 a.m. Eastern, allowing investors to participate by visiting Cardinal Health's Investor Relations page without requiring an access code, thereby enhancing information transparency.
- Availability of Materials: Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months, facilitating easy access for investors to review the information at their convenience and strengthening communication between the company and its investors.
- Company Overview: Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient services, and is committed to driving continuous improvement and innovative solutions that enhance people's lives through a customer-centric focus.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
- Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
- Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
- Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
See More
Cardinal Health Expands Ac-225 Production Capacity Significantly
- Production Capacity Boost: Cardinal Health has added a high-capacity production line at its Center for Theranostics Advancement in Indianapolis, significantly increasing the supply of cGMP-compliant Ac-225 to meet the growing demand for cancer therapies.
- Clinical Trial Support: To date, Cardinal Health's Ac-225 has supported over 15 clinical trials worldwide, reflecting the company's extensive engagement in advancing targeted alpha therapies and enhancing its position in pharmaceutical innovation.
- Market Demand Response: Since announcing routine global production at scale at the end of 2024, Cardinal Health has quadrupled its weekly output, with expectations to continue increasing production capacity in 2026 to meet the rapidly growing demand for targeted alpha therapies.
- Supply Chain Assurance: According to VP Shane Thrasher, expanding Ac-225 production capacity is a critical advancement for the industry and patients, ensuring reliable access to targeted alpha therapies and preparing for larger commercial volumes in the future.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
- Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
- Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
- Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
See More
Cardinal Health to Release Q3 FY2026 Financial Results on April 30
- Earnings Release Schedule: Cardinal Health is set to release its third-quarter financial results for fiscal year 2026 on April 30, prior to the opening of trading on the New York Stock Exchange, ensuring timely access to critical information for investors.
- Webcast Discussion: The company will host a webcast discussion of the financial results starting at 8:30 a.m. Eastern, allowing investors to participate by visiting Cardinal Health's Investor Relations page without requiring an access code, thereby enhancing information transparency.
- Availability of Materials: Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months, facilitating easy access for investors to review the information at their convenience and strengthening communication between the company and its investors.
- Company Overview: Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient services, and is committed to driving continuous improvement and innovative solutions that enhance people's lives through a customer-centric focus.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
- Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
- Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
- Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
See More
Cardinal Health Appoints New Board Chair
- Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
- Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
- Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
- Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
See More
